Navigation Links
Cetero Research Seminars Provide Insights on Designing Accelerated Proof-of-Concept Studies

CARY, N.C., April 20, 2011 /PRNewswire/ -- Cetero Research, the leading early-phase contract research organization (CRO), will present a scientific seminar series for pharmaceutical and biotechnology researchers entitled "Practical Insights for Designing and Conducting an Accelerated Proof-of-Concept Program." The seminars, the continuation of a series that occurred in the fall of 2010, will share best practices on how to run successful studies by developing robust protocols, ensuring safety and recruiting effectively for innovative accelerated proof-of-concept study designs. The six-city tour will kick off on April 28 in Bridgewater, NJ.

"Pharmaceutical and biotechnology companies are very interested in the efficiencies that this approach can bring to their early-phase clinical studies. However, there are a number of complexities involved in developing these studies to successfully combine multiple protocols into a single study," said Troy W. McCall, Ph.D., Chief Executive Officer of Cetero Research. "Cetero leadership and independent industry experts will share case studies and best practices."

The scientific sessions will cover three aspects of Accelerated Proof-of-Concept (AcPOC) study design and conduct: protocol development, safety in first-in-human trials and patient recruitment strategies. The seminars will offer real-world advice on creating studies that strike a balance between the strict schedule to which accelerated studies must adhere and the built-in flexibility that these trials require for troubleshooting, efficiency and regulatory approval.

"With the accelerated approach, the protocol must be a living document that can be adjusted as you move through each component of the study. There needs to be flexibility in adapting to feedback from regulators and reactions from participants," said Alan Copa, PharmD, President, Clinical Operations - Fargo for Cetero Research. "With the increasing demand for this type of study, it is important to discuss the best practices that will ensure the most efficient, robust study design possible."

Each seminar will last two hours and include three presentations as well as a question and answer session. The series schedule is as follows:

  • Thursday, April 28 — Bridgewater, NJ
  • Wednesday, May 4 — Northbrook, IL
  • Tuesday, May 10 — King of Prussia, PA
  • Wednesday, May 11 — Cambridge, MA
  • Tuesday, May 17 — La Jolla, CA
  • Wednesday, May 18 — San Jose, CA

The Cetero sessions are complimentary, but pre-registration is required. For more information about the series or to register for a session, please email, visit or call 877-7CETERO.

About Cetero Research

Cetero Research, the leading early-phase contract research organization (CRO), has conducted more than 20,000 clinical pharmacology studies, more than any other CRO. With facilities across North America, Cetero offers flexible, high-quality clinical development services in a range of therapeutic areas, including asthma and allergy, dermatology and diabetes, as well as bioanalytical services to support clinical, preclinical drug and biomarker analysis for small and large molecules. It uses innovative approaches, such as the Accelerated-Proof-of-Concept study design, to provide key decision-making data earlier in the development process. A pioneer in the pharmaceutical and biotechnology space, Cetero prioritizes ensuring the safety of its patient and normal healthy study participants, reporting high-quality, reliable data and providing on-time results. For more information, visit or call 877.7CETERO.

SOURCE Cetero Research
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cetero Research Announces Completion of 20,000th Early-Phase Clinical Study
2. Cetero Research Names Dr. Roger Hayes President of Bioanalytical Operations
3. Cetero Research Launches Seminar Series on Accelerated Proof-of-Concept in Drug Development
4. Cetero Research Leads Industry in Human Allergy Models
5. Premier Research Re-brands its Medical Device Business Unit to D-TARGET
6. Australian Center Readies Brain Research Program for Addition of Elekta MEG System
7. Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research
8. Thorne Research and Integrative Health Resources Establish Joint Venture to Provide Full Range of Services in Practice Development, Patient and Clinician Education, and Access to Nutritional Supplements in Integrative Medicine
9. New Research Links Restless Legs Syndrome (RLS) to Cardiovascular Disease
10. Kanzius Cancer Research Foundation Earns $1 for Each New Facebook Fan
11. Phase I Research of Extended-Release Topiramate Shows Less Fluctuation in Plasma Levels
Post Your Comments:
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):